PMID- 9304705
OWN - NLM
STAT- MEDLINE
DCOM- 19971029
LR  - 20190905
IS  - 0080-0015 (Print)
IS  - 0080-0015 (Linking)
VI  - 144
DP  - 1998
TI  - Molecular monitoring of residual disease in chronic myelogenous leukemia patients 
      after therapy.
PG  - 36-45
AB  - The degree of tumor load reduction after therapy, which is determined by the 
      degrees of cytoreduction and cytogenetic response, is an important prognostic 
      factor for patients with chronic myelogenous leukemia (CML). Conventional 
      metaphase analysis is considered to be the "gold standard" for evaluating 
      cytogenetic response. The frequency of cytogenetic analysis can be reduced 
      considerably if patients are monitored by molecular methods, such as quantitative 
      Southern blot, fluorescence in situ hybridization (FISH), quantitative western 
      blot, or competitive reverse transcriptase polymerase chain reaction (RT-PCR). 
      Molecular methods can be performed on peripheral blood specimens and are 
      therefore less invasive than cytogenetic analyses of bone marrow metaphases. 
      Furthermore these techniques are applicable to Ph-negative/BCR-AbL-positive 
      cases. Results obtained by Southern blotting, western blotting, and FISH are 
      readily quantifiable but their sensitivity is not generally superior to that of 
      cytogenetic methods. RT-PCR is by far the most sensitive method. Quantitative 
      RT-PCR analysis is the method of choice for monitoring patients after bone marrow 
      transplantation (BMT). Using competitive PCR in patients after BMT, reappearance 
      and/or rising levels of BCR-ABL transcripts can be detected prior to relapse. All 
      complete cytogenetic responders to interferon-alpha are positive for BCR-ABL 
      transcripts. The level of residual disease spans a range over found orders of 
      magnitude. In both interferon-alpha-treated patients and patients after BMT a 
      good correlation between BCR-ABL transcript numbers per microgram of RNA and 
      cytogenetic results has been found. Variables in the competitive PCR assay may be 
      controlled for by quantification of transcripts of the normal ABL gene as an 
      internal standard. We suggest a stepwise strategy for diagnosis and follow-up of 
      CML patients employing molecular methods.
FAU - Hochhaus, A
AU  - Hochhaus A
AD  - Third Medical Clinic, University of Heidelberg, Mannheim, Germany.
FAU - Reiter, A
AU  - Reiter A
FAU - Skladny, H
AU  - Skladny H
FAU - Reichert, A
AU  - Reichert A
FAU - Saussele, S
AU  - Saussele S
FAU - Hehlmann, R
AU  - Hehlmann R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Germany
TA  - Recent Results Cancer Res
JT  - Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans 
      les recherches sur le cancer
JID - 0044671
RN  - EC 2.7.10.2 (Fusion Proteins, bcr-abl)
SB  - IM
MH  - Blotting, Southern
MH  - Fusion Proteins, bcr-abl/genetics
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*diagnosis/genetics/therapy
MH  - Neoplasm, Residual
MH  - Polymerase Chain Reaction
RF  - 31
EDAT- 1997/09/26 00:00
MHDA- 1997/09/26 00:01
CRDT- 1997/09/26 00:00
PHST- 1997/09/26 00:00 [pubmed]
PHST- 1997/09/26 00:01 [medline]
PHST- 1997/09/26 00:00 [entrez]
AID - 10.1007/978-3-642-46836-0_5 [doi]
PST - ppublish
SO  - Recent Results Cancer Res. 1998;144:36-45. doi: 10.1007/978-3-642-46836-0_5.